Although the introduction of stem cell transplantation and novel agents has improvedsurvival, multiple myeloma (MM) is still difficult to cure. Alternative approaches areclearly needed to prolong the survival of patients with MM. Dendritic cell (DC) therapyis a very promising tool immunologically in MM. We developed a method to generatepotent DCs with increased Th1 polarization and migration ability for inducing strongmyeloma-specific cytotoxic T lymphocytes. In this review, we discuss how the efficacyof cancer immunotherapy using DCs can be improved in MM.